Disease course following High Disease Activity Status revealed patterns in SLE.
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
14 07 2021
14 07 2021
Historique:
received:
04
05
2021
accepted:
05
07
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
14
8
2021
Statut:
epublish
Résumé
We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited information on this subset of patients who achieve this. All consenting patients of the Monash Lupus Cohort who had at least 12 months of observation were included. HDAS was defined as SLEDAI-2K ≥ 10 ever, and HDAS episode as the period from the first HDAS clinic visit until attainment of LLDAS. We examined the associations of different HDAS patterns with the likelihood of damage accrual. Of 342 SLE patients, 151 experienced HDAS at least once, accounting for 298 HDAS episodes. The majority of HDAS patients (76.2%) experienced Recurrent HDAS (> 1 HDAS visit), and a smaller subset (47.7%) had Persistent HDAS (consecutive HDAS visits for longer than 2 months). Recurrent or Persistent HDAS patients were younger at diagnosis and more likely to experience renal or serositis manifestations; persistent HDAS patients were also more likely to experience neurological manifestations. Baseline SLEDAI greater than 10 was associated with longer HDAS episodes. Recurrent and Persistent HDAS were both associated with an increased likelihood of damage accrual. The total duration of HDAS episode greater than 2 years and experiencing multiple HDAS episodes (≥4) was also associated with an increased likelihood of damage accrual (OR 1.80, 95% CI 1.08-2.97, p = 0.02, and OR 3.31, 95% CI 1.66-13.26, p = 0.01, respectively). HDAS episodes have a highly variable course. Recurrent and Persistent HDAS, and longer duration of HDAS episodes, increased the risk of damage accrual. In addition to a major signifier of severity in SLE, its resolution to LLDAS can determine the subsequent outcome in SLE patients.
Sections du résumé
BACKGROUND
We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited information on this subset of patients who achieve this.
METHODS
All consenting patients of the Monash Lupus Cohort who had at least 12 months of observation were included. HDAS was defined as SLEDAI-2K ≥ 10 ever, and HDAS episode as the period from the first HDAS clinic visit until attainment of LLDAS. We examined the associations of different HDAS patterns with the likelihood of damage accrual.
RESULTS
Of 342 SLE patients, 151 experienced HDAS at least once, accounting for 298 HDAS episodes. The majority of HDAS patients (76.2%) experienced Recurrent HDAS (> 1 HDAS visit), and a smaller subset (47.7%) had Persistent HDAS (consecutive HDAS visits for longer than 2 months). Recurrent or Persistent HDAS patients were younger at diagnosis and more likely to experience renal or serositis manifestations; persistent HDAS patients were also more likely to experience neurological manifestations. Baseline SLEDAI greater than 10 was associated with longer HDAS episodes. Recurrent and Persistent HDAS were both associated with an increased likelihood of damage accrual. The total duration of HDAS episode greater than 2 years and experiencing multiple HDAS episodes (≥4) was also associated with an increased likelihood of damage accrual (OR 1.80, 95% CI 1.08-2.97, p = 0.02, and OR 3.31, 95% CI 1.66-13.26, p = 0.01, respectively).
CONCLUSION
HDAS episodes have a highly variable course. Recurrent and Persistent HDAS, and longer duration of HDAS episodes, increased the risk of damage accrual. In addition to a major signifier of severity in SLE, its resolution to LLDAS can determine the subsequent outcome in SLE patients.
Identifiants
pubmed: 34261522
doi: 10.1186/s13075-021-02572-1
pii: 10.1186/s13075-021-02572-1
pmc: PMC8278658
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
191Informations de copyright
© 2021. The Author(s).
Références
Arthritis Rheumatol. 2018 Feb;70(2):266-276
pubmed: 29073347
Arthritis Rheum. 2013 Aug;65(8):2143-53
pubmed: 23754628
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Lupus. 2010 Jan;19(1):49-51
pubmed: 19910390
Lupus. 2016 Sep;25(10):1122-40
pubmed: 27497257
Lupus Sci Med. 2020 May;7(1):
pubmed: 32467293
Ann Rheum Dis. 2016 Sep;75(9):1615-21
pubmed: 26458737
Ann Rheum Dis. 2018 May;77(5):706-713
pubmed: 29420200
Ann Intern Med. 2005 Jun 21;142(12 Pt 1):953-62
pubmed: 15968009
Rheumatology (Oxford). 2014 Jan;53(1):85-9
pubmed: 24067885
Ann Rheum Dis. 2019 May;78(5):629-633
pubmed: 30679152
Ann Rheum Dis. 2012 Aug;71(8):1343-9
pubmed: 22337213
Rheumatology (Oxford). 2020 Oct 1;59(10):2930-2938
pubmed: 32107560
Med J Aust. 2017 Mar 20;206(5):194-195
pubmed: 28301780